Untangling gut and joint inflammation in arthritis 

New study reveals distinct triggers for gut and joint inflammation using germ-free mouse technology 

Ghent, 11 September 2023 – Scientists at the VIB-UGent Center for Inflammation Research shed new light on the relationship between gut and joint inflammation. Their study challenges previous assumptions that joint inflammation is driven by alterations in the gut, including changes in the intestinal microbiome. The new study proves that severe arthritis can develop in the complete absence of intestinal bacteria and intestinal inflammation. Disconnecting this gut-joint axis opens the door to tissue- and patient-specific therapeutic interventions. The work appears in EMBO Molecular Medicine. 

The gut-joint axis 

Arthritis is a common complication in inflammatory bowel disease (IBD), and vice versa, arthritis patients often develop gut inflammation. This has led to the concept of a 'gut joint axis' – a shared disease pathway that suggests that gut inflammation and microbial triggers can instigate inflammation in the joints 

However, correlation does not necessarily equal causation. ​ 

To study the role of the microbiome in various diseases, including arthritis, the lab of Prof. Lars Vereecke (VIB-UGent) established the first Belgian germ-free mouse facility, in which two transgenic mouse models of gut & joint inflammation were established. Surprisingly, when these mice were maintained under sterile conditions, they were protected from intestinal inflammation but still developed severe joint inflammation, indicating that intestinal bacteria drive gut inflammation, but are dispensable for joint inflammation. ​ 

"Inflammation in the gut and joints has long been thought to be mechanistically linked, but our study challenges this hypothesis," said Prof. Vereecke. "While shared inflammatory pathways may contribute to both gut and joint inflammation, our research indicates that the triggers to activate these pathways are different in each tissue, and require tissue-specific therapeutic interventions." 

Top: germ-free mouse facilities; bottom: arthrosis in ankles of specific pathogen-free (SPF) and germ-free (GF) mice.

Different triggers 

These findings indicate that microbial factors can drive gut inflammation, while sterile mechanisms appear to contribute more significantly to joint inflammation. The study's implications are far-reaching, offering potential insights into the development of tissue-specific therapeutic interventions. By understanding the distinct molecular triggers for gut and joint inflammation, researchers may be able to design interventions that target the underlying causes of each condition more precisely. 

"Our results illustrate the complexity of inflammatory diseases and emphasize the importance of considering tissue-specific mechanisms," said Alexandra Thiran (VIB-UGent), first author of the study. "Our research opens up new avenues for investigating the drivers of inflammation and developing novel treatments for arthritis and related conditions." 

The study not only challenges existing theories about the gut-joint axis but also highlights the need for continued research into the underlying causes of inflammatory diseases. The researchers hope that their findings will inspire further exploration into the intricate connections between different bodily systems and lead to more effective treatments for patients. 


Publication 

Thiran et al. Sterile triggers drive joint inflammation in TNF and IL-1b dependent mouse arthritis models. EMBO Molecular Medicine, 2023. 

Joran Lauwers

Joran Lauwers

Press Contact, VIB

Share

Latest stories

Website preview
Blocking lipid production in healthy lung cells can reduce lung metastasis
Leuven, 17 March 2026 - Scientists from the VIB–KU Leuven Center for Cancer Biology, in collaboration with the Francis Crick Institute, have discovered how cancer cells can exploit healthy lung cells to support metastatic tumor growth in the lungs. In two complementary studies published in Nature Cell Biology and Cancer Discovery, they show that tumors use lipids produced by lung cells as signals, and that decreasing the lipid production of lung cells can decrease metastasis. The findings point to new therapeutic strategies that target lung cell lipid production, rather than cancer cells themselves, which may also help refine patient selection for ongoing clinical trials targeting this pathway.
press.vib.be
Website preview
Researchers identify major genetic risk factor for rare form of dementia
Antwerp, 12 March 2026 - Researchers at VIB and Antwerp University have identified a major genetic risk factor for a rare form of frontotemporal dementia. The discovery, published today in Nature Genetics, provides a biological entry point for a disease subtype that has been difficult to study. It could not only help to improve diagnosis and patient stratification, but also opens up new avenues toward targeted treatments.
press.vib.be
Website preview
Protealis Announces Regulatory Approval of its First Biological Solution MagNfixTM and Launch of Five New Soybean Varieties
Ghent (Belgium), 11 March 2026 – Protealis, the European specialist in non-GMO legume seeds and seed technologies, today announces several milestones that significantly strengthen its position in a fast-growing European soybean market. The company has obtained European regulatory approval from EFCI1 (EU Fertilising Products Regulation (FPR) 2019/1009) for MagNfix™, its first biological solution, which is a proprietary soybean inoculant seed coating that is designed to support higher soybean yield and protein content. In addition, Protealis has secured the registration of five new soybean varieties across four European countries. This includes the introduction of two new maturity group (MG) 000 soybean varieties in Poland, the registration of its first maturity group 0000 ultra-early soybean variety in France, and a new soy variety registration for Belgium. In Germany, Protealis received registration for its second 00 MG soybean variety suited for the regions in southern Germany...
press.vib.be

About VIB Press

VIB is an independent research institute that translates insights in biology into impactful innovations for society. Collaborating with the five Flemish universities, it conducts research in plant biology, cancer, neuroscience, microbiology, inflammatory diseases, artificial intelligence and more. VIB connects science with entrepreneurship and stimulates the growth of the Flemish biotech ecosystem. The institute contributes to solutions for societal challenges such as new methods for diagnostics and treatments, as well as innovations for agriculture. 

Learn more at www.vib.be.

Contact

Suzanne Tassierstraat 1 9052 Zwijnaarde

+32 9 244 66 11

press@vib.be

vib.be